Infinity Pharma: Up after co gives cancer study update, earnings forecast

Infinity Pharmaceuticals

14/03/2019 12:15

** Drug developer's shares  INFI.O  up nearly 7 pct at $1.65
premarket after co announces it will initiate mid-stage breast
cancer study
    ** Co says agreement with Roche  ROG.S  in which Roche will
supply its breast cancer treatment Tecentriq to INFI for use in
the study of patients with triple negative breast cancer
 urn:newsml:reuters.com:*:nPn5LvlkPa
    ** INFI says will initiate study in the second half of 2019
    ** INFI also said it expects net loss for 2019 to range from
$30 mln to $40 mln vs analysts' estimates of net loss of $41.5
mln  urn:newsml:reuters.com:*:nPn9BDjR0a
    ** Up to Wednesday's close, stock up ~31 pct this year

 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,
outside the U.S. +91  80 67491576; Reuters Messaging:
Aakash.B.thomsonreuters.com@reuters.net))